This page shows the publications co-authored by Vijaya Ramesh and Xandra Breakefield.
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:169-180.
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Sci Adv. 2021 01; 7(2).
Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiol Dis. 2015 Oct; 82:22-31.
TorsinB--perinuclear location and association with torsinA. J Neurochem. 2004 Jun; 89(5):1186-94.
The early onset dystonia protein torsinA interacts with kinesin light chain 1. J Biol Chem. 2004 May 07; 279(19):19882-92.
TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. J Neurosci Res. 2003 Apr 15; 72(2):158-68.
Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet. 2000 May 22; 9(9):1403-13.
Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Res. 2003 Oct 03; 986(1-2):12-21.
TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis. 2003 Feb; 12(1):11-24.
A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol. 2001 Jul; 159(1):339-44.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.